An Open Label Post Licensure Trial to Evaluate the Safety and Immunogenicity of Indigenously Manufactured Killed Bivalent (O1 and O139) Whole Cell Oral Cholera Vaccine (Shanchol).

Trial Profile

An Open Label Post Licensure Trial to Evaluate the Safety and Immunogenicity of Indigenously Manufactured Killed Bivalent (O1 and O139) Whole Cell Oral Cholera Vaccine (Shanchol).

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Cholera vaccine inactivated (Primary)
  • Indications Cholera
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 16 Sep 2013 Status changed from recruiting to completed as reported by Clinical Trials Registry - India record.
    • 20 Nov 2012 Planned end date changed from 1 Mar 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
    • 29 Mar 2012 Trial phase changed from II to IV as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top